Repligen Corporation (NASDAQ:RGEN) Receives Average Rating of “Moderate Buy” from Analysts

Repligen Corporation (NASDAQ:RGEN) has been assigned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $173.8462.

A number of equities research analysts recently issued reports on the company. HSBC assumed coverage on Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective on the stock. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Royal Bank Of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Finally, Barclays lifted their price objective on shares of Repligen from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th.

Repligen Price Performance

Repligen stock opened at $164.98 on Wednesday. The business’s 50 day simple moving average is $153.86 and its 200 day simple moving average is $133.24. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a market cap of $9.29 billion, a price-to-earnings ratio of 8,253.13, a PEG ratio of 3.71 and a beta of 1.11. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. During the same period in the previous year, the company posted $0.43 earnings per share. The business’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts forecast that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 25,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director directly owned 100,743 shares in the company, valued at approximately $15,804,561.84. The trade was a 19.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 49,382 shares of company stock valued at $7,676,802. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Twin Tree Management LP purchased a new position in Repligen during the first quarter worth about $29,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Repligen during the 3rd quarter valued at about $29,000. Hantz Financial Services Inc. grew its holdings in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares in the last quarter. CWM LLC increased its position in shares of Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares during the last quarter. Finally, Center for Financial Planning Inc. increased its position in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 126 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.